Marketdash
Back to Stock Market News

Johnson & Johnson Pulls Plug on Eczema Drug Trial After Disappointing Results

MarketDash Editorial Team
2 hours ago
Johnson & Johnson terminated its Phase 2b study of an experimental atopic dermatitis treatment early after interim results failed to meet efficacy targets, though the drug proved safe and well-tolerated.

Johnson & Johnson (JNJ) announced Friday that it's shutting down a mid-stage clinical trial for an experimental eczema treatment after interim results came up short. The Phase 2b DUPLEX-AD study, testing JNJ-95475939 for moderate to severe atopic dermatitis, hit predefined criteria for early termination when the data didn't show the level of efficacy researchers were hoping for.

The silver lining? The drug was well-tolerated by patients, meaning safety wasn't the issue here. It just didn't work well enough to justify continuing.

For context, atopic dermatitis is the medical term for eczema, a chronic skin condition that causes dry, intensely itchy, inflamed skin. Depending on your skin tone, affected areas can appear red, darker brown, or grey, and the skin often becomes cracked. It's uncomfortable, persistent, and there's ongoing demand for better treatment options.

Johnson & Johnson launched this Phase 2 trial back in February with plans to enroll around 240 participants. The study was originally scheduled to wrap up by August 2026, but those plans are now off the table following the interim analysis.

The drug itself came to Johnson & Johnson through an acquisition. In 2024, the pharmaceutical giant bought Proteologix Inc., a private biotech company, for $850 million in cash with the potential for additional milestone payments down the road. That deal gave Johnson & Johnson access to PX128, which was ready to enter Phase 1 development for both moderate to severe atopic dermatitis and moderate to severe asthma, plus PX130, a preclinical asset also targeting moderate to severe atopic dermatitis.

This isn't Johnson & Johnson's first clinical disappointment in recent months. Back in November, the company reported that its Phase 2b AuTonomy study of posdinemab failed to achieve statistical significance in slowing clinical decline in patients with early Alzheimer's disease. The company characterized that study as a first-of-its-kind precision approach to evaluating targeted intervention in early Alzheimer's, but the results ultimately didn't pan out.

Clinical trial failures are part of the drug development process, of course, but back-to-back setbacks in different therapeutic areas highlight just how difficult it is to bring new treatments to market, even for a company with Johnson & Johnson's resources and expertise.

Johnson & Johnson shares were essentially flat Friday, trading up 0.02% at $207.83.

Back to Stock Market News

Johnson & Johnson Pulls Plug on Eczema Drug Trial After Disappointing Results

MarketDash Editorial Team
2 hours ago
Johnson & Johnson terminated its Phase 2b study of an experimental atopic dermatitis treatment early after interim results failed to meet efficacy targets, though the drug proved safe and well-tolerated.

Johnson & Johnson (JNJ) announced Friday that it's shutting down a mid-stage clinical trial for an experimental eczema treatment after interim results came up short. The Phase 2b DUPLEX-AD study, testing JNJ-95475939 for moderate to severe atopic dermatitis, hit predefined criteria for early termination when the data didn't show the level of efficacy researchers were hoping for.

The silver lining? The drug was well-tolerated by patients, meaning safety wasn't the issue here. It just didn't work well enough to justify continuing.

For context, atopic dermatitis is the medical term for eczema, a chronic skin condition that causes dry, intensely itchy, inflamed skin. Depending on your skin tone, affected areas can appear red, darker brown, or grey, and the skin often becomes cracked. It's uncomfortable, persistent, and there's ongoing demand for better treatment options.

Johnson & Johnson launched this Phase 2 trial back in February with plans to enroll around 240 participants. The study was originally scheduled to wrap up by August 2026, but those plans are now off the table following the interim analysis.

The drug itself came to Johnson & Johnson through an acquisition. In 2024, the pharmaceutical giant bought Proteologix Inc., a private biotech company, for $850 million in cash with the potential for additional milestone payments down the road. That deal gave Johnson & Johnson access to PX128, which was ready to enter Phase 1 development for both moderate to severe atopic dermatitis and moderate to severe asthma, plus PX130, a preclinical asset also targeting moderate to severe atopic dermatitis.

This isn't Johnson & Johnson's first clinical disappointment in recent months. Back in November, the company reported that its Phase 2b AuTonomy study of posdinemab failed to achieve statistical significance in slowing clinical decline in patients with early Alzheimer's disease. The company characterized that study as a first-of-its-kind precision approach to evaluating targeted intervention in early Alzheimer's, but the results ultimately didn't pan out.

Clinical trial failures are part of the drug development process, of course, but back-to-back setbacks in different therapeutic areas highlight just how difficult it is to bring new treatments to market, even for a company with Johnson & Johnson's resources and expertise.

Johnson & Johnson shares were essentially flat Friday, trading up 0.02% at $207.83.